Search Result

Results for "

Glucose dehydrogenase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldehyde Dehydrogenase (ALDH) (1) PDHK (2) Phosphoglycerate Dehydrogenase (PHGDH) (1) Bacterial (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (1) Endogenous Metabolite (12) PDI (1) PDK-1 (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (3) Metabolic Disease (14)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Succinate Dehydrogenase Lactate Dehydrogenase Dihydroorotate Dehydrogenase Isocitrate Dehydrogenase (IDH) Methylenetetrahydrofolate Dehydrogenase (MTHFD) Phosphoglycerate Dehydrogenase (PHGDH) Aldehyde Dehydrogenase (ALDH) GLUT SGLT PDHK 15-PGDH 17β-HSD 11β-HSD

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3186

Glucose dehydrogenase, recombinant Microorganisms	Endogenous Metabolite	Metabolic Disease
Glucose dehydrogenase, recombinant Microorganisms is a oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP ⁺ to NADPH or, to a lesser extent, NAD ⁺ to NADH. Glucose dehydrogenase (GDH) accepts both NAD ⁺ and NADP ⁺ as cofactors and can be used for the regeneration of NADH and NADPH .

HY-E70014

FAD-dependent glucose dehydrogenase FAD-GDH; Glucose 1-dehydrogenase	Endogenous Metabolite	Others
FAD-dependent glucose dehydrogenase (EC 1.1.5.9), or glucose dehydrogenase (FAD)/Pseudomonas glucose dehydrogenase. Glucose 1-dehydrogenase is an enzyme used as a regeneration cofactor to convert glucose and NAD(P) into NAD(P)H and gluconic acid .

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Endogenous Metabolite	Metabolic Disease Cancer
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-P3186A

NAD-dependent Glucose dehydrogenase GDH-NAD	Endogenous Metabolite	Others
NAD-dependent Glucose dehydrogenase (EC 1.1.1.47) is an enzyme used as a regeneration cofactor to convert glucose and NAD(P) into NAD(P)H and gluconic acid .

HY-125863A

Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) G6PD (Leuconostoc sp., recombinant)	Endogenous Metabolite	Metabolic Disease
Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) is an NADP-dependent enzyme in the pentose phosphate pathway, which is one of the ways glucose is metabolized. Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) can be used to quantify ATP, glucose, and creatine kinase .

HY-E70419

*PQQ-Dependent glucose* dehydrogenase, microorganism**	Others	Others
PQQ-Dependent glucose dehydrogenase, microorganismyes PQQnovel nanostructure platform for fluorescence analysis of glucose dehydrogenase-dependent glycogenase. Fluorescence signals were generated under ultraviolet excitation at a wavelength (365 nm).

HY-141851

UDP-glucose dehydrogenase	Others	Others
UDP-glucose dehydrogenase is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-125863C

Glucose-6-phosphate dehydrogenase, Bacillus sp. G6PD, Bacillus sp.	Endogenous Metabolite	Others
Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the conversion of glucose-6-phosphate into 6-phosphogluconolactone, and produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate in this process. Glucose-6-phosphate dehydrogenase, Bacillus sp. can be used in research about diabetic complications .

HY-125863B

Glucose 6-phosphate dehydrogenase (yeast, recombinant) G6PD (yeast, recombinant)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-125954B

UDP-galacturonic acid trisodium	Biochemical Assay Reagents	Metabolic Disease
UDP-galacturonic acid trisodium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase .

HY-W027038

Ethyl mandelate	Others	Others
Ethyl mandelate is an important intermediate in pharmaceutical synthesis. Ethyl mandelate can be synthesized by short-chain dehydrogenase/reductase (SDR) .

HY-123962

G6PD activator AG1 3 Publications Verification	Others	Metabolic Disease
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC₅₀ of 3 µΜ . G6PD activator AG1 reduces hemolysis of human erythrocytes .

HY-114509

Anilazine	Bacterial	Infection Metabolic Disease
Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .

HY-E70020

UDP-Glc dehydrogenase (UGDH)	Others	Others
UDP-Glc dehydrogenase (UGDH) catalyzes is a NAD+-dependent enzyme that catalyzes the two-fold oxidation of UDP-glucose (UDP-Glc) to produce UDP-glucuronic acid. UDP-Glc dehydrogenase (UGDH) is a key enzyme in the nucleotide-sugar interconversion pathway necessary for biosynthesis of many cell-wall polysaccharides .

HY-128578

KPLH1130	PDHK	Metabolic Disease Inflammation/Immunology
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice .

HY-Z0031

(R)-(-)-1,2-Propanediol	Endogenous Metabolite	Metabolic Disease
(R)-(-)-1,2-Propanediol is a (R)-enantiomer of 1,2-Propanediol that produced from glucose in Escherichia coli expressing NADH-linked glycerol dehydrogenase genes .

HY-117240

NCT-502 5 Publications Verification	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC₅₀ of 3.7 μM against PHGDH .

HY-W010342

6-Aminonicotinamide Maximum Cited Publications 6 Publications Verification	Others	Cancer
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP ⁺-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (K_i=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin, in killing cancer cells .

HY-162586

PDHK-IN-7	Others	Cancer
PDHK-IN-7 (compound 32) is an inhibitor of pyruvate dehydrogenase kinase with an IC₅₀ value of 17 nM.PDHK-IN-7 activates PDH in rat livers and has a glucose-lowering effect in Zucker fatty rats .

HY-146240

ALDH1A1-IN-3	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
ALDH1A1-IN-3 (compound 57) is an excellent and selective *aldehyde dehydrogenase* 1A1 (ALDH1A1) inhibitor with an IC₅₀** value of 0.379 μM. ALDH1A1-IN-3 can effectively improve glucose consumption in HepG2 cells. ALDH1A1-IN-3 can be used for researching glucose metabolism improvement .

HY-W107464

G6PDi-1 2 Publications Verification	PDI	Metabolic Disease Inflammation/Immunology
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC₅₀ of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .

HY-W005629

Leelamine	Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-125954

Uridine diphosphate glucuronic acid UDP-α-D-glucuronic acid	Endogenous Metabolite	Metabolic Disease
Uridine diphosphate glucuronic acid (UDP-α-D-glucuronic acid) is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

HY-125954A

Uridine diphosphate glucuronic acid ammonium UDP-α-D-glucuronic acid ammonium	Endogenous Metabolite	Metabolic Disease
Uridine diphosphate glucuronic acid (UDP-GlcA) ammonium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid (ammonium) is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid (ammonium), as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

HY-121744

PS10 2 Publications Verification	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	999 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 999 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

999 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 999 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Type

HY-125954A

Uridine diphosphate glucuronic acid ammonium UDP-α-D-glucuronic acid ammonium	Gene Sequencing and Synthesis
Uridine diphosphate glucuronic acid (UDP-GlcA) ammonium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid (ammonium) is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid (ammonium), as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

Uridine diphosphate glucuronic acid ammonium

UDP-α-D-glucuronic acid ammonium

Gene Sequencing and Synthesis

Uridine diphosphate glucuronic acid (UDP-GlcA) ammonium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid (ammonium) is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid (ammonium), as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

(R)-(-)-1,2-Propanediol	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
(R)-(-)-1,2-Propanediol is a (R)-enantiomer of 1,2-Propanediol that produced from glucose in Escherichia coli expressing NADH-linked glycerol dehydrogenase genes .

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

PF-07247685	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

Uridine diphosphate glucuronic acid UDP-α-D-glucuronic acid	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite
Uridine diphosphate glucuronic acid (UDP-α-D-glucuronic acid) is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

Uridine diphosphate glucuronic acid ammonium UDP-α-D-glucuronic acid ammonium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Uridine diphosphate glucuronic acid (UDP-GlcA) ammonium is a cofactor that is formed by the catalytic activity of UDP-glucose dehydrogenase. Uridine diphosphate glucuronic acid (ammonium) is a central precursor in sugar nucleotide biosynthesis and common substrate for C4-epimerases and decarboxylases releasing UDP-galacturonic acid (UDP-GalA) and UDP-pentose products, respectively. Uridine diphosphate glucuronic acid (ammonium), as a glucuronic acid donor, can be used for for the research of the conjugation of bilirubin in the endoplasmic recticulum .

Species:	Human (1)
Tag:	His (3) Tag Free (2) Strep (2)
Source:	HEK293 (1) E. coli (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P70283

	G6PD Protein, Human (HEK293, His) rHuGlucose-6-phosphate 1-dehydrogenase/G6PD, His; Glucose-6-Phosphate 1-dehydrogenase; G6PD	Human	HEK293
	The G6PD protein is a rate-limiting enzyme in the oxidative pentose phosphate pathway located in the cytosol, which is crucial for the catabolism of carbohydrates in glycolysis. The primary function of G6PD is to provide reducing power in the form of NADPH and generate pentose phosphates, helping the cell resist oxidative stress and regulate metabolic rates. Additionally, the activity of G6PD is associated with cancer progression. The G6PD protein (Human, HEK293, His) is a recombinant G6PD protein expressed in HEK293 cells, with a C-terminal His tag, and consists of 514 amino acids (A2-L515) .

HY-P702123

	GOX2015 Protein, Gluconobacter oxydans Glucose 1-dehydrogenase	Others	E. coli
	The GOX2015 protein showed a significant ability to oxidize D-glucose and D-mannose, showing a clear 15-fold preference for the latter. This catalytic efficiency is strictly dependent on the presence of NADP, emphasizing its important role as an oxidative cofactor. GOX2015 Protein, Gluconobacter oxydans is the recombinant GOX2015 protein, expressed by E. coli , with tag free. The total length of GOX2015 Protein, Gluconobacter oxydans is 265 a.a., .

HY-P702124

	GOX2015 Protein, Gluconobacter oxydans (His, Strep) Glucose 1-dehydrogenase	Others	E. coli
	The GOX2015 protein showed a significant ability to oxidize D-glucose and D-mannose, showing a clear 15-fold preference for the latter. This catalytic efficiency is strictly dependent on the presence of NADP, emphasizing its important role as an oxidative cofactor. GOX2015 Protein, Gluconobacter oxydans (His, Strep) is the recombinant GOX2015 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of GOX2015 Protein, Gluconobacter oxydans (His, Strep) is 265 a.a., .

HY-P701895

	gdh2 Protein, Saccharolobus solfataricus gdh2; Glucose 1-dehydrogenase 2; GDH 2; GlcDH 2	Others	E. coli
	gdh2 protein acts as a catalyst in the NAD(P)(+)-dependent oxidation of D-glucose to D-gluconate through gluconolactone. Demonstrating versatility, it can utilize both NAD(+) and NADP(+) as electron acceptors. gdh2 plays a pivotal role in the degradation of glucose, specifically through a non-phosphorylative variant of the Entner-Doudoroff pathway. gdh2 Protein, Saccharolobus solfataricus is the recombinant gdh2 protein, expressed by E. coli , with tag free. The total length of gdh2 Protein, Saccharolobus solfataricus is 367 a.a., .

HY-P701896

	gdh2 Protein, Saccharolobus solfataricus (His, Strep) gdh2; Glucose 1-dehydrogenase 2; GDH 2; GlcDH 2	Others	E. coli
	gdh2 protein acts as a catalyst in the NAD(P)(+)-dependent oxidation of D-glucose to D-gluconate through gluconolactone. Demonstrating versatility, it can utilize both NAD(+) and NADP(+) as electron acceptors. gdh2 plays a pivotal role in the degradation of glucose, specifically through a non-phosphorylative variant of the Entner-Doudoroff pathway. gdh2 Protein, Saccharolobus solfataricus (His, Strep) is the recombinant gdh2 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of gdh2 Protein, Saccharolobus solfataricus (His, Strep) is 367 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80688

	Glucose 6 Phosphate Dehydrogenase Antibody G6PD; Glucose-6-phosphate 1-dehydrogenase; G6PD	WB, IHC-P, IP	Human, Rat
	Glucose 6 Phosphate Dehydrogenase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 59 kDa, targeting to Glucose 6 Phosphate Dehydrogenase. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Rat.